We derive pipeline candidates both from our own research activities, and from successful collaboration with a number of global pharmaceutical businesses Ongoing royalties from frovatriptan, the migraine pain reliever we've successfully developed and brought to market, provide operating revenues which together with cash raised from two recent public financings provide a robust cash runway New drug candidates enter the pipeline as a result of our own independent research, or through collaborative research programmes such as those with Servier and GSK